Center For Asset Management LLC Vertex Pharmaceuticals Inc Transaction History

Center For Asset Management LLC

  • $168 Million
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024
SELL
$392.81 - $485.53 $3,928 - $4,855
-10 Reduced 0.58%
1,714 $803,000
Q4 2023

Jan 22, 2024
SELL
$343.0 - $410.68 $410,228 - $491,173
-1,196 Reduced 40.96%
1,724 $701,000
Q3 2023

Oct 27, 2023
SELL
$338.18 - $362.46 $29,083 - $31,171
-86 Reduced 2.86%
2,920 $1.02 Million
Q2 2023

Jul 24, 2023
BUY
$314.42 - $351.91 $622,237 - $696,429
1,979 Added 192.7%
3,006 $1.06 Million
Q1 2023

Apr 24, 2023
BUY
$283.23 - $323.1 $290,877 - $331,823
1,027 New
1,027 $323,000

Others Institutions Holding VRTX

# of Institutions
1,724
Shares Held
222M
Call Options Held
1.58M
Put Options Held
1.36M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Center For Asset Management LLC Portfolio

Follow Center For Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Center For Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Center For Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email